Literature DB >> 7648397

Activation of HIV expression by CD30 triggering in CD4+ T cells from HIV-infected individuals.

E Maggi1, F Annunziato, R Manetti, R Biagiotti, M G Giudizi, A Ravina, F Almerigogna, N Boiani, M Alderson, S Romagnani.   

Abstract

CD30 is a member of the tumor necrosis factor receptor superfamily, preferentially expressed by T cells producing type 2 helper (Th2) cytokines, whose ligand (CD30L) has been identified on B cells, activated macrophages, and a subset of activated T cells. We show here that cross-linking CD30 with an agonistic CD30-specific monoclonal antibody, as well as with CD30L+ CD8+ T cell clones or CD30L+ B cells, enhanced HIV replication in CD4+ T cells from HIV-infected individuals, and such a potentiating effect was inhibited by anti-CD30L antibody. The anti-CD30L antibody also exerted a suppressive effect on spontaneous HIV replication occurring in lymph node cells from an HIV-sero-positive patient, showing CD30L expression by both B and CD8+ T lymphocytes. Thus, CD30 triggering by CD30L-expressing cells may plan an important role in the activation of HIV expression from latently infected CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648397     DOI: 10.1016/1074-7613(95)90094-2

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  14 in total

1.  Regulation of CD30 antigen expression and its potential significance for human disease.

Authors:  M E Kadin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Upregulation of human immunodeficiency virus (HIV) replication by CD4 cross-linking in peripheral blood mononuclear cells of HIV-infected adults.

Authors:  S Than; N Oyaizu; S Tetali; J Romano; M Kaplan; S Pahwa
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms.

Authors:  R Horie; V Gattei; K Ito; S Imajo-Ohmi; T Tange; J Miyauchi; A Pinto; M Degan; A De Iuliis; F Tassan Mazzocco; F M Rossi; M Higashihara; T Watanabe
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

4.  OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection.

Authors:  Y Takahashi; Y Tanaka; A Yamashita; Y Koyanagi; M Nakamura; N Yamamoto
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2.

Authors:  C S Duckett; R W Gedrich; M C Gilfillan; C B Thompson
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

6.  Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.

Authors:  Paul G Rubinstein; Page C Moore; Michelle A Rudek; David H Henry; Juan C Ramos; Lee Ratner; Erin Reid; Elad Sharon; Ariela Noy
Journal:  AIDS       Date:  2018-03-13       Impact factor: 4.177

7.  Genetic drift can dominate short-term human immunodeficiency virus type 1 nef quasispecies evolution in vivo.

Authors:  U Plikat; K Nieselt-Struwe; A Meyerhans
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue.

Authors:  Joanne Fanelli Panus; Craig A Smith; Caroline A Ray; Terri Davis Smith; Dhavalkumar D Patel; David J Pickup
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

9.  CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival.

Authors:  C S Duckett; C B Thompson
Journal:  Genes Dev       Date:  1997-11-01       Impact factor: 11.361

Review 10.  Biology of human TH1 and TH2 cells.

Authors:  S Romagnani
Journal:  J Clin Immunol       Date:  1995-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.